Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.

Paediatric Rheumatology International Trials Organisation, Genoa, Italy.
Arthritis & Rheumatology (Impact Factor: 7.76). 04/2009; 61(4):509-17. DOI: 10.1002/art.24343
Source: PubMed


To investigate the health-related quality of life (HRQOL) change over time, as measured by the Child Health Questionnaire (CHQ), and its determinants in patients with active juvenile dermatomyositis (DM).
We assessed patients with juvenile DM at both baseline and 6 months of followup, and healthy children age < or =18 years. Potential determinants of poor HRQOL included demographic data, physician's and parent's global assessments, muscle strength, functional ability as measured by the Childhood Health Assessment Questionnaire (C-HAQ), global disease activity assessments, and laboratory markers.
A total of 272 children with juvenile DM and 2,288 healthy children were enrolled from 37 countries. The mean +/- SD CHQ physical and psychosocial summary scores were significantly lower in children with juvenile DM (33.7 +/- 11.7 versus 54.6 +/- 4.1) than in healthy children (45.1 +/- 9.0 versus 52 +/- 7.2), with physical well-being domains being the most impaired. HRQOL improved over time in responders to treatment and remained unchanged or worsened in nonresponders. Both physical and psychosocial summary scores decreased with increasing levels of disease activity, muscle strength, and parent's evaluation of the child's overall well-being. A C-HAQ score >1.6 (odds ratio [OR] 5.06, 95% confidence interval [95% CI] 2.03-12.59), child's overall well-being score >6.2 (OR 5.24, 95% CI 2.27-12.10), and to a lesser extent muscle strength and alanine aminotransferase level were the strongest determinants of poor physical well-being at baseline. Baseline disability and longer disease duration were the major determinants for poor physical well-being at followup.
We found that patients with juvenile DM have a significant impairment in their HRQOL compared with healthy peers, particularly in the physical domain. Physical well-being was mostly affected by the level of functional impairment.

Download full-text


Available from: Sulaiman Mohammed Al-Mayouf, Sep 28, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The reflective liquid crystal displays, SBTN (sub-twist nematic LCD) and XSTN (non-compensated super-twist nematic LCD), were investigated. They operate using different principles compared to conventional TN and STN. They have shown great advantages such as brightness, electro-optic performance, tolerable production margin, economical cost, etc. They are a new generation of LCDs deserving further development
    No preview · Conference Paper · Feb 1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: The lifting scheme is used as a motivational tool for designing a better temporal subband scheme in video coding. The new subband coding scheme replaces the typical Haar filterbank. A simple criterion is used for the detection of scene changes in video sequences, and a modification to the Haar lifting scheme is developed that allows for adjusting the filterbank near a scene change. The new edge adaptive lifting scheme is applied to a scene change in video data and achieves improved performance at scene change frames when compared with the lifting Haar filterbank
    No preview · Conference Paper · Feb 1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Juvenile dermatomyositis (JDM) is a rare, potentially life-threatening systemic autoimmune disease primarily affecting muscle and skin. Recent advances in the recognition, standardised assessment and treatment of JDM have been greatly facilitated by large collaborative research networks. Through these networks, a number of immunogenetic risk factors have now been defined, as well as a number of potential pathways identified in the aetio-pathogenesis of JDM. Myositis-associated and myositis-specific autoantibodies are helping to sub-phenotype JDM, defined by clinical features, outcomes and immunogenetic risk factors. Partially validated tools to assess disease activity and damage have assisted in standardising outcomes. Aggressive treatment approaches, including multiple initial therapies, as well as new drugs and biological therapies for refractory disease, offer promise of improved outcomes and less corticosteroid-related toxicity.
    Full-text · Article · Oct 2009 · Best practice & research. Clinical rheumatology
Show more